These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2410765)

  • 41. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 42. Monthly dosage form of leuprolide approved by FDA.
    Oncology (Williston Park); 1989 Apr; 3(4):139. PubMed ID: 2518158
    [No Abstract]   [Full Text] [Related]  

  • 43. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.
    Schally AV
    BJU Int; 2007 Jul; 100 Suppl 2():2-4. PubMed ID: 17594347
    [No Abstract]   [Full Text] [Related]  

  • 44. Other chemotherapy regimens including mitoxantrone and suramin.
    Siu LL; Moore MJ
    Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hypercalcemia: a finding indicative of a prostatic adenocarcinoma].
    Llarena Ibarguren R; Acha Pérez M; Zabala Egurrola JA; Pertusa Peña C
    Actas Urol Esp; 1989; 13(5):409-10. PubMed ID: 2531967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estrogen therapy for prostate carcinoma.
    Presti JC
    JAMA; 1996 Apr; 275(15):1153. PubMed ID: 8609673
    [No Abstract]   [Full Text] [Related]  

  • 47. Leuprolide acetate for the treatment of endometriosis.
    Miller JD
    Prog Clin Biol Res; 1990; 323():337-41. PubMed ID: 2106145
    [No Abstract]   [Full Text] [Related]  

  • 48. Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer.
    Nicholson RI; Walker KJ; Davies P
    Cancer Surv; 1986; 5(3):463-86. PubMed ID: 3555778
    [No Abstract]   [Full Text] [Related]  

  • 49. Decapeptyl in the treatment of advanced prostatic cancer: comparative study with pulpectomy.
    Botto H; Richard F; Mathieu F; Camey M
    Prog Clin Biol Res; 1989; 303():53-60. PubMed ID: 2528740
    [No Abstract]   [Full Text] [Related]  

  • 50. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs.
    Winkel CA
    Postgrad Med; 1994 May; 95(6):111-8. PubMed ID: 8170869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Use of LHRH agonists in the therapy of advanced cancer of the prostate].
    Fretin J
    Arch Esp Urol; 1989; 42 Suppl 2():209-11. PubMed ID: 2700882
    [No Abstract]   [Full Text] [Related]  

  • 53. Chemotherapy and prostate cancer.
    Dacker R
    Radiol Technol; 1997; 68(3):194-5. PubMed ID: 9008013
    [No Abstract]   [Full Text] [Related]  

  • 54. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog.
    Yu SS; Connolly MK; Berger TG; McCalmont TH
    J Am Acad Dermatol; 2006 Feb; 54(2 Suppl):S58-9. PubMed ID: 16428002
    [No Abstract]   [Full Text] [Related]  

  • 55. [Luteinizing hormone-releasing hormone agonists for treatment of prostatic cancer].
    Gez E
    Harefuah; 1990 Apr; 118(8):483-6. PubMed ID: 2192959
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer.
    Bourdin S; Karam G; Clemain P; Bouchot O; Peuvrel P; Lacoste J; Auvigne J
    J Int Med Res; 1990; 18 Suppl 1():74-8. PubMed ID: 2108888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate.
    Sharifi R; Lee M; Ojeda L; Ray P; Stobnicki M; Guinan P
    Urology; 1985 Aug; 26(2):117-24. PubMed ID: 3927551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Does the pharmacological class effect between the different luteinizing hormone releasing hormone analogues used in the treatment of prostate cancer have to be assumed?].
    Vilar-González S; Maldonado-Pijuan X; Andrés-García I
    Actas Urol Esp; 2010 Oct; 34(9):749-57. PubMed ID: 20843451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gonadotropin-releasing hormone analogs and prostatic cancer.
    Swanson LJ; Seely JH; Garnick MB
    Crit Rev Oncol Hematol; 1988; 8(1):1-26. PubMed ID: 2964939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan.
    Johns WD; Garnick MB; Kaplan WD
    Clin Nucl Med; 1990 Jul; 15(7):485-7. PubMed ID: 2116949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.